These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33920054)

  • 61. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
    Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.
    Hargadon KM
    Cell Mol Life Sci; 2023 Jan; 80(2):40. PubMed ID: 36629955
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.
    Huang Y; Liang D; Liu J; Zeng J; Zeng Y
    Comb Chem High Throughput Screen; 2017; 20(5):430-439. PubMed ID: 28302019
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.
    Bleve A; Durante B; Sica A; Consonni FM
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
    Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
    Front Immunol; 2021; 12():716710. PubMed ID: 34539652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer.
    Wu T; Wu X; Wang HY; Chen L
    Cancer Commun (Lond); 2019 Apr; 39(1):21. PubMed ID: 30999966
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TGF-beta: a master immune regulator.
    Larson C; Oronsky B; Carter CA; Oronsky A; Knox SJ; Sher D; Reid TR
    Expert Opin Ther Targets; 2020 May; 24(5):427-438. PubMed ID: 32228232
    [No Abstract]   [Full Text] [Related]  

  • 72. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differentiation and Regulation of T
    Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
    Front Immunol; 2021; 12():669474. PubMed ID: 34012451
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.
    Gayen S; Mukherjee S; Dasgupta S; Roy S
    Apoptosis; 2024 Dec; 29(11-12):1879-1913. PubMed ID: 39354213
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
    Sharma P; Allison JP
    Cell; 2015 Apr; 161(2):205-14. PubMed ID: 25860605
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy.
    Laureano RS; Vanmeerbeek I; Sprooten J; Govaerts J; Naulaerts S; Garg AD
    Immunol Rev; 2024 Jan; 321(1):71-93. PubMed ID: 37937803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward.
    Jennings MR; Munn D; Blazeck J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.